bluuebunny/crossref_metadata_2025_split huggingface dataset:
The Role of CD4+CD25+ T Cell and FOXP3 in Allogeneic Hematopoietic Stem Celltransplantation.
Authors: Liu Yuejun , Wu De Pei , Li Caixia 
Published: April 2020

Abstract
Objective To explore the relationship among CD4+CD25+ regulatory T cell, the expression of FOXP3 mRNA levels of donor BM and GVHD in allogeneic hematopoietic stem cell transplantation(allo-HSCT). Methods (1)Thirty patients undergoing allo-HSCT were enrolled in this study. The levels of donor CD4+CD25+ regulatory T cell were compared in the patients with GVHD and those without GVHD by immnofluorescence and flowcytometry. (2)The donor BM expressions of FOXP3 mRNA levels were analyzed by using reverse transcriptase polymerase chain reaction (RT-PCR). Results (1)All patients achieved engraftment. ANC ≥ 0.5′109•L−1and Plt ≥ 20′109•L−1 were at day 14(range, 12~15)and day 18 (range, 15~25) respectively. Acute GVHD occurred in 15 of 30 patients(50.0%) with gradeII°-IV° aGVHD (40.0%). Chronic GVHD developed in 6 (extensive 2, limited 4) out of 30 patients (20.0%). 3 patients relapsed.(2)The levels of CD4+CD25+ regulatory T cell pre-and pro-mobilization were (2.67±0.38) % and (5.01± 1.33)% respectively, no difference were observed(P&gt;0.05).(3)Patients with I°~II° aGVHD demonstrated higher donor-type CD4+CD25+ immune regulatory T cell level than those with III°~IV° aGVHD; Patients with III°~IV° aGVHD showed much lower donor-type CD4+CD25+ immune regulatory T cell level than those without GVHD; no difference were observed between patients withI°~II° aGVHD and those without aGVHD.(4)The transcripts of FOXP3 donor BM were detected in seven donors of thirty recipients who received allo-HSCT. Three relapsed after transplantation;two developedI°aGVHD; and the other two had no GVHD. Donor BM FOXP3 transcripts were never detected in patients with II°~IV° aGVHD. Conclusion(1)Donor-type CD4+CD25+ immune regulatory T cell level was relative to recipient II°~IV° aGVHD. Up-grade donor-type CD4+CD25+ immune regulatory T cell level could reduce the incidence of aGVHD.(2)Donor BM FOXP3 transcripts were detected in patients without serious aGVHD after transplantation.
Basiliximab in the Treatment of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation.
Authors: Ma Xiao , Wu De Pei , Sun Aining 
Published: April 2020

Abstract
Objective: To explore the efficiency and side-effects of basiliximab in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
Patients and Methods: Basiliximab, a chimeric interleukin-2 receptor antagonist, was evaluated in twenty-eight patients with steroid-refractory acute graft-versus-host disease after Allo-HSCT. Patients were transplanted from a related (n=9) or unrelated (n=6) HLA- identical donor or haplo-identical donor(n=13) because of chronic myelogenous leukemia (chronic phase n=11, accelerate phase n=2), acute myeloid leukemia (n=8), high risk acute lymphocytic leukemia (n=6), high risk non-Hodgkin’s lymphoma (n=1). Basiliximab was given at a dose of 20mg on the day after steroid-refractory acute GVHD had developed, and was repeated on day 4 in all these cases. The efficiency and side-effects of basiliximab were observed at the same time. Basiliximab was repeated again 4 weeks later in some cases of having response.
Result: None had infusion-associated or other side-effects after the treatment with basiliximab. Twenty-two of 28 patients (78.57%) responded to basiliximab, 15/28(53.57%) had a complete response (CR) of acute GVHD and 7/28 (25.00%) had a partial response (PR). Six of 28 patients (21.43%) did not respond. Chronic GVHD developed in 15/24 evaluable patients. Only 9/24 evaluable patients have no chronic GVHD and all had a complete response before.
Conclusion: Basiliximab is safe and effective in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) after allogeneic stem cell transplantation(Allo-SCT).
Comparative Study of Chimerism Dynamics between Allogenic Bone Marrow Transplantation and Nonmyeloablative Stem Cell Transplantation.
Authors: Tang Xiaowen , Wu De Pei , Sun Aining 
Published: April 2020

Abstract
Objective To explore whether the dynamics and outcome of chimerism are different between allogenic bone marrow transplantation (allo-BMT) and nonmyeloablative stem cell transplantation (NST) these two kinds of transplant strategies in order to define factors that significantly influence the early engraftment of donor stem cells.
Methods A retrospective comparative study was performed between 20 patients undergoing BMT and 18 patients receiving NST. There are several differences between NST and standard allo-BMT, such as conditioning regimens, the source and the quantity of hematopoietic stem cells and the protocal of GVHD prophylaxis. But component of two groups patients were similar. Sequential monitoring of chimerism were performed in 38 patients in different periods post transplantation using multiple short tandem repeat(STR) amplification by fluorescence labeling polymerase chain reaction(PCR) combined with a capillary electrophoresis.
Results
The median age of recipient, median quantity of MNC, CD34+ cells and T lymphocyte cells of NST were significantly higher compared with the BMT. The median time for absolute neutrophils recovery of NST(without G-CSF) was similar to that of BMT. While compared to BMT, NST lead to faster engraftment of platelets. The establishment of full donor chimerism (FDC) of NST was much more earlier than that of BMT (1 month VS 3 months, p=0.01). In the early post-transplant period(up to day 30), there was an apparent increase in the incidence of full donor chimerism (FDC) following NST compared with BMT(38.9% VS 20%, p=0.019). Whereas a significantly lower incidence of mixed chimerism(MC) occurred in recipients of NST compare to BMT.(61.2% VS 80%, p=0.02). It suggest that in the early stage after transplantation, the engraftment of donor cells of NST was more rapid than that of BMT. The major relevant factor causing full donor chimerism formation seems to be the high quantity of donor CD34+ cells and T lymphocyte cells. Fludarabine-based reduced-intensity conditioning didn’t result in a significant delay of donor cell engraftment compared to standard conditioning regimen. The incidence of chronic GVHD was much higher in group of NST than that of BMT group(80% VS 50%, p=0.007).
This finding was related to that patients of NST group received the higher doses of CD34+ cells. Conclusion Factors that significantly influence the early kinetics of donor chimerism and donor cell engraftment after transplantation were the quantity of stem cell and T lymphocyte cell of grafts.
Nonmyeloablative Allogeneic Stem Cell Transplantation for a Case of Refractory Systemic Lupus Erythematosus.
Authors: Lu Quanyi , Niu Xiaoqing , Guo Yong , Lu Lulu , Liu Delong 
Published: April 2020

Abstract
Autologous stem cell transplantation (SCT) was effective for severe SLE and may have curative potential in some cases, but recurrence of the disease was still a major problem. Allogeneic SCT for autoimmune disease has been shown to induce long-term remission through graft-versus-autoimmunity effect. Non-myeloablative SCT can induce full-donor Chimerism with much less toxicity. We report a case of 43 year old Chinese female with severe SLE refractory to high dose cyclophosphamide and had lupus nephritis. The patient also had avascular necrosis and was bed-bound. Peripheral blood stem cell transplantation were done from an HLA-matched sibling after non-ablative conditioning using ATG, Fludarabine and busulfan. The patient had good performace status nad had no recurrence at the last follow-up 16 months post-transplantation.
Allogeneic Stem Cell Transplantation for Lymphoid Malignancies.
Authors: Novitzky Nicolas , Thomas Valda , Du Toit Cecile , McDonald Andrew 
Published: April 2020

Abstract
Haematopoietic stem cell transplantation may be curative therapy for selected patients with haematological malignancies. We reviewed our experience in individuals with lymphoid neoplasms (excluding multiple myeloma) who received an allogeneic stem cell transplant from HLA identical sibling donors. Myeloablative conditioning was radiation based (n= 46) or with chemotherapy (n= 12). GvHD prophylaxis was with T-cell depletion (CAMPATH-1 g or H,“ in the bag”). 17 received a BMT while 41 had PBPC (median CD34+ 2.64). Patients receiving BMT had no further immunosuppression, while 12 patients who received PBPC grafts received prednisone 30 mg and another 21 were treated with therapeutic doses of cyclosporine for 90 days. The diagnosis was indolent lymphoma in 14 (median 3 treatment modalities), aggressive variant in 18 (7 with transformed DLBC; 6 with lymphoblastic lymphoma, 2 mantle cell), 5 had chemotherapy responsive (median 4 treatments) recurrent Hodgkin’s lymphoma and 21 had lymphoblastic leukaemia (18 in CR1). Median age was younger in patients with ALL (24 years; range 15–45) than lymphoma (47 years; 29–57; p&lt; 0.001). At a median follow up of 1173 (32–5598) days, 20 have died and 67% survive disease free. Death was from disease recurrence in 15 (10 with ALL), and it was transplant related in 4 while one patient died of AIDS. Survival was significantly worse in patients with lymphoblastic leukaemia (48%; p&lt; 0.001), while 76% of those with lymphomas survive in unmaintained remission (median 1493 days; 32–5598). Survival was significantly associated with diagnosis of lymphoma (p&lt; 0.01), CD34+ cell number above median (p= 0.04) and absence of GvHD (p&lt; 0.01). We conclude that despite T-cell depletion allogeneic stem cell transplantation is very effective therapeutic strategy in patients with lymphoma, as disease recurrence was low (relapse 6/37; p= 0.03), suggesting remaining graft vs. lymphoma effect. To the contrary, this therapy remains less satisfactory for patients with ALL who have poor prognostic factors.
Graft-Versus-Lymphoma Effect in Hodgkin’s Disease: A Possible Role in Maintaining a Disease Control.
Authors: Pastano Rocco , Andreola Giovanna , Gigli Federica , Saronni Luca , Cassatella Maria C. , Peccatori Fedro , Martinelli Giovanni 
Published: April 2020

Abstract
Introduction: non-myeloablative and highly immunosuppressive conditioning regimen instead of conventional bone marrow transplantation have been recently developed. The aim of this treatment is to establish a mixed chimerism and to allow the donor cell-mediated graft versus-tumor effect to occur. This is a well known effect in disease like CML and AML and much less investigated in Hodgkin Lymphoma.
Patients and methods: from September 2003 to November 2004, 5 pts affected by chemorefractory Hodgkin’s lymphoma, underwent a non-myeloablative conditioning regimen followed by allogeneic peripheral blood stem cell transplantation (PBSCT). Median age was 28 ys (range 26–33), 4 M and 1 F, all pts had failed previous conventional treatment including autologous PBSCT. Conditioning regimen were the following: Fludarabine 30 mg/mq, from day −4 to −2 followed by TBI 2Gy on day 0 in 2 pts; TBI 2Gy alone two month after an autologous PBSCT in 1pt; thiotepa 5mg/kg x2, Fludarabine 30mg/mq, Cyclofosfamide 30 mg/kg in 1pt or Rituximab 600 mg/mq on day −5; fludarabine 30 mg/mq + Cyclofosfamide 30 mg/kg from day −4 to day −3 in the other one. All patients received donor peripheral stem cell infusion on day 0. Prophylaxis of aGVHD was performed with Cyclosporine (6.25 mg/kg) po from day −3 to day +36 followed by a rapid tapering until day +56 and Mycophenolate Mofetil (15mg/kg) po from day 0 to +27.
Results: All pts experienced a complete engraftment, obtained a complete response after transplantation and 3/5 them experienced hepatic and/or cutaneous cGvHD. At a median follow-up of 13 months 2/3 pts, who received TBI and/or Fludarabine, are alive after 681 days, 612 days from transplantation and are in CR and SD respectively; both of them had cGvHD; the third one has died at +132 for cerebral hemorrhage. One of the remaining two patients has died at +200 in CR for septic shock after cGvHD, and the last one is still alive in +410 in PD, with no sign of cGvHD.
Conclusions: although limited, our data seem to suggest that even in pts affected by Hodgkin’s lymphoma with a chemoresitant disease, the development of cGvHD after a reduced conditioning allogeneic PBSCT, mostly immunosuppressive, seems to be associated with the presence of a graft-versus lymphoma effect able to mediate a good control of the disease.
Graft vs. Tumor Effects (GVT) in Non Myeloablative Stem Cells Transplant (NST) in Relapse Hodgkin Disease (HD) after Autologous Bone Marrow Transplant (ABMT).
Authors: Milone Jorge H. , Bordone Javier A. , Kusminsky Gustavo , Foncuberta Cecilia , Garcia Juan , Rolon Juliana Martinez , Bullorsky Eduardo , Dengra Cristina , Cerutti Ider 
Published: April 2020

Abstract
The relapse post ABMT is a terminal stage complication in HD. The allogenic transplant contributes to a different therapeutic approach through the immune anti tumor effect of the Graft versus Host Disease (GVHD)
The NST variant of the procedure diminishes the risks of transplant related mortality (TRM) and is associated with induction of mixed hematopoietic chimerism when either HLA-identical sibling or unrelated donor are used, and that powerful GVT effects can be achieved against advanced chemotherapy/resistant hematology disease.
The feasibility, risk and effectiveness of the NST, is analyzed in 13 patients with relapsed HD after ABMT. Seven women and six men with a median age of 26 years old. They had received ≥ of 3 therapeutic lines that included the high doses and the ABMT. The period betwen the diagnosis to NST, had a median time of 36 months. The patients were conditioned with Fludarabine based schemes plus: Melphalan 8, Cyclofosfamide 3, TBI 1, Busulfan 1. The sources of stem cells were, with a HLA-identical sibiling donors in 12 patients, and in 1 with non related donor. 4 patients died due to complications associated with the BMT (TRM 28 %): shock 2, sepsis 1, thrombotic microangiophaty 1. Half of the patients developed some form of GVHD, or it was induced by donor lymphocytes infusion. With an average follow up of 15 months (range: 1–56), 7 patients are alive, 5 of them developed GVHD and are in CR, the other 2 have a short follow up (28 and 75 days). Of 4 patients who progressed only 1 present GVHD. The NST is a feasible procedure in HD relapsed post ABMT. The TRM is 28 %. In this group there is a clear relationship between the control of HD and the appearance of GVHD.
A Successful Syngeneic Bone Marrow Transplant after an Ortotopic Liver Transplantation for Fulminant Hepatitis - Case Report.
Authors: Silla Lucia , Paz Alessandra , Astigarraga Claudia , Zago Alethea , Brum Caroline , Bittencourt Rosane , Fogliatto Laura , Friederich João R. , Leugeur Denise , Silveira Themis R. 
Published: April 2020

Abstract
We report the case of a 12 year old girl admitted to the hospital in August 2004 presenting acute hepatic failure with grade IV encephalopathy without stigmatic of chronic liver disease. Investigation for A, B and C hepatitis was negative as well as the tests for HIV, Toxoplasmosis, EBV, B19 parvovirus and CMV. Diagnosed as fulminant hepatitis she received an ortotopic hepatic transplant 25 days after admission. She had an excellent clinical recovery on tracolimus for immunossupression, except for an asymptomatic pancytopenia unresponsive to drug dose reduction, which progressed to severe bone marrow aplasia in a four months period. A second round of virus screening tests was still negative. She was then submitted to bone marrow transplantation from her twin identical sister utilizing 50mg/kg/day of cyclophosphamide for two days as conditioning regimen. She received 6.6 x 106 CD34+ cells/kg and engrafted at D+22. She was discharged at D+ 33 on tracolimus without any sign of liver or bone marrow rejection. She is presently in complete clinical recovery after 7 months of BMT. This is, from our knowledge, the first report of a successful hepatic transplant followed by an equally successful syngeneic bone marrow transplant.
Prolonged Survival in an Elderly Patient with CD4+ CD56+ Lymphoma of the Skin with Autologous Peripheral Blood Stem Cell Transplantation (PBSCT).
Authors: Nath Rajneesh , Abo Stephen M. 
Published: April 2020

Abstract
CD4+ CD56+ lymphomas are recently described rare hematological neoplasms thought to be originating from plasmacytoid dendritic cells. Clinical features typically include cutaneous nodules associated with lymphadenopathy and/or splenomegaly and bone marrow involvement during the disease course. Complete remission (CR) is frequently obtained (around 80%) with polychemotherapy. However, median time to relapse is about 9 (range 3–18) months and median survival is only 13 months. Age &gt; 60 years is a poor prognostic factor. Long term survival has only been reported following allogeneic SCT (Bone Marrow Transplantation32, 637–646, 2003; Blood99,1556–1563, 2002). We report a case of CD4+ CD56 + lymphoma with prolonged survival after an autologous PBSCT. A 71-year-old male presented in the fall of 2001 with facial erythema that progressed to several purple cutaneous nodules also involving his trunk. Skin biopsy done in June 2002 confirmed the diagnosis of CD4+ CD56+ lymphoma of the skin. Staging studies including CT scan of the chest, abdomen and pelvis, and bone marrow aspiration and biopsy were negative. The patient received chemotherapy with CHOPE (cytoxan 750 mg/m2, adriamycin 50 mg/m2, vincristine 1.4 mg/2, prednisone 100mg x 5 days, etoposide 120 mg/m2) for six cycles starting June 2002, and achieved a CR with disappearance of all skin lesions. CT scan of the chest pretransplant revealed a single 2 cm paratracheal lymph node that was also PET positive. Stem cells were collected using cytoxan 4 gms/m2 followed by 10 mcg/kg/day of G-CSF. The patient underwent autologous stem cell transplantation in February 2003 using BEAM (carmustine 300mg/m2 day −6, etopside 200mg/2 days −5 to −2, cytarabine 400mg/m2 days −5 to −2, melphalan 140 mg/m2 day -1) as a preparative regimen. Neutrophil engraftment occurred on day 10 and platelets engrafted on day 14 post SCT. The paratracheal lymph node was still visible on the PET scan 6 months post SCT. However, restaging studies at one year and beyond have all been negative for disease reoccurrence including a CT chest that revealed a calcified paratracheal lymph node that was negative on PET scan. The patient continues to be in complete remission 37 months from diagnosis and 30 months post SCT. The aggressive nature of CD4+ CD56+ lymphoma is evident by its 9-month median time to relapse and short survival. Therefore, aggressive treatment protocols incorporating stem cell transplant should be utilized in their management and should not be limited to only younger patients. As illustrated by our patient, the use of autologous stem cell transplant in the elderly can be done safely with encouraging results.
Comparison of Hematopoietic Reconstitution after Autologous Transplantation Using Stem Cells after Short- (&lt;12 Months) and Longer-Term Cryostorage.
Authors: Lowenthal Raymond M. , Burbury Kate L. , Ragg Scott J. , Brillant Corinne 
Published: April 2020

Abstract
High-dose chemotherapy with autologous hemopoietic stem cell (HSC) transplantation is an important treatment option for patients with refractory or relapsed non-Hodgkin or Hodgkin lymphoma (NHL or HL). Although it is customary to collect the HSCs at the time the need is apparent, in theory collections carried out at an earlier stage of the disease - preferably when the patient is in remission - may have advantages in that 1) such HSCs will have been less exposed to damaging cytotoxic chemotherapy and 2) early collections may be less likely to be contaminated with malignant cells. However such "prophylactic" or "rainy day" harvests may need to be stored for extended periods before use, raising questions about their functional capacity. Although laboratory studies of the effects of long-term storage on the viability and proliferative capacity of cryopreserved HSCs have demonstrated that the cells remain functional, there have been few studies of clinical outcomes after their reinfusion. Because we have had a long-standing policy of carrying out "rainy day" harvests, we have had the opportunity to retrospectively compare rates of neutrophil and platelet engraftment, and 30-day transplant related mortality (TRM), of patients undergoing HSC transplantation after short-term (&lt;1 year) and longer-term (range 1–9.3 years, median 2.2 years) cryostorage. Of the 133 NHL and HL patients transplanted at our hospital between 1985 and 2005, 98 were in the short-term and 35 in the longer-term group. TRM was 7/98 and 1/35 for the short- and longer-term groups, respectively (P=0.7); no deaths occurred in the 77 patients transplanted after 1998. Hematopoietic reconstitution was achieved in all 125 patients who survived 30 days. Neutrophil recovery (absolute neutrophil count &gt;0.5 x 109/L) was achieved by 12.2 ± 4.2 (SD) days and 14.2 ± 6.5 days post-reinfusion for the short- and longer-term groups respectively (P=0.14). Platelet support was required for a mean 6.6 ± 9.5 and 7.5 ± 7.1 days, respectively (P=0.7). These clinical results demonstrate that HSCs after long-term cryostorage retain engraftment potential similar to that of HSCs stored for lesser periods and that such cells are safe and efficacious for autologous transplantation.
Augmented Preparative Regimens Using Total Body Irradiation or BCNU Prior to Autologous Stem Cell Transplant (AuSCT) Are Well-Tolerated and Yield Substantial Rates of Progression-Free Survival in Patients with Poor Risk Hodgkin Lymphoma (HL) or Diffuse Large B-Cell Lymphoma (DLBCL).
Authors: Ritchie David S. , Seymour John F. , Thompson Sarah , McManus Michael , Prince Miles 
Published: April 2020

Abstract
Introduction: AuSCT using conditioning such as BEAM, for relapsed DLBCL and HL results in progression-free survival (PFS) of 60% of cases in second complete remission (CR). Those who do not achieve a second CR or who have primary refractory disease have significantly reduced benefit from BEAM/AuSCT. Consequently, we have been offering dose intensified conditioning prior to AuSCT with the Stanford regimen using Etoposide 60mg/kg day-4, Cyclophosphamide 100mg/kg day-2 and either BCNU 15mg/kg day-6 or fractionated TBI 12Gy days-8 to -5 to patients with poor risk haematologic malignancy.
Methods: We assessed the outcome of AuSCT in 46 patients with poor risk haematologic disease; DLBCL (n=16), HL (n=16), multiply relapsed indolent lymphoma (n=8) and aggressive “other” lymphomas (n=6) who received conditioning with either the BNCU (n=31) or TBI (n=15) protocols. Of the 32 patients with HL or DLBCL, 28 had previously failed to achieve a CR to salvage chemotherapy; PR (21/32) or induction failure/early progression (7/32).
Results: There were no transplant-related deaths among the 32 HL or DLBCL patients. One case of fatal radiation pneumonitis occurred following consolidative radiotherapy 6 months post AuSCT. The PFS for the combined HL/DLBCL cohort was 65±9% at 12, and 61±9% at 24 months. The 24 month PFS by BCNU or TBI regimen was 63% and 57% respectively (p=0.56). The 24 month PFS for HL or DLBCL treated with either regimen was 54±13% and 68±12% respectively (P=0.34) Additional groups were too heterogeneous to statistically assess. 1 of 6 patients with aggressive “other” lymphoma maintained a durable remission (39 months) and 4/8 patients with indolent lymphoma have ongoing CR at 9 – 59 months follow up.
Conclusions: Stanford TBI or BCNU conditioning prior to AuSCT are well-tolerated and result in substantial rates of PFS in patients with poor risk HL or DLBCL.